Innoforce Pharmaceuticals (“Innoforce”), a biopharmaceutical innovation and partnership company, today announces that it has opened a new Advanced Cell and Gene Therapy Development Facility in Hangzhou, China. Analytical development (AD) and Process development (PD) represents a critical step towards providing services for potential clients in their cell & gene therapy product development to support clinical trials and further commercialization. Innoforce’s development facility further strengthens the company’s capability in analytical development, process characterization, validation, and staff training for a broad range of cell and gene products.
The facility is set up as an AD-PD development laboratory to provide analytical method development and qualification, quality control preparations, process development, and building platform technology approach in preparation for the launch of Innoforce’s GMP manufacturing facility in 2022.
“The capability of analytical and process development largely dictates the success of any cell and gene therapy development. It is understood by all players in the industry that this is a critical aspect of cell and gene therapy product development. Innoforce’s Development Facility aims to address the crucial need for quality and expertise in the Process and Analytical Development areas,” commented Yuling Li, CEO of Innoforce.
The new facility significantly accelerates Innoforce’s ability to develop and deliver cost-effective, robust, scalable, analytical capability and processing technologies to drive client’s programs’ efficient and rapid progression to GMP manufacturing. Innoforce will provide end-to-end manufacturing services, including GMP commercial manufacturing of plasmid DNA, viral vector, and cell therapy products by the middle of 2022. Innoforce’s new Development Facility is located at the ChuanHua Science and Technology Building, Xiaoshan Innovation Zone.